Valèria Richart

Dr. Valèria Richart

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2020 in Vaccines
Verified
Journal Article
Open access
PDF file
LLLorna Leal
Lorna Leal
CFCsaba Fehér
Csaba Fehér
VRValèria Richart
Valèria Richart
BTBerta Torres
Berta Torres
FGFelipe García
Felipe García
A functional Human immunodeficiency Virus (HIV) cure has been proposed as an alternative to antiretroviral treatment for life, and therapeutic vaccines represent one of the most promising approaches. The goal of therapeutic vaccination is to augment virus-specific immune responses that have an impact on HIV viral load dynamics. To date, the agreed feature to evaluate the effects of these therapeutic interventions is analytical antiretroviral treatment interruption (ATI), at least until we find a reliable biomarker that can predict viral control. Different host, immunologic, and virologic markers have been proposed as predictors of viral control during ATI after therapeutic interventions. This review describes the relevance of ATI and the different surrogate markers of virological control assessed in HIV therapeutic vaccine clinical trials.

22 August 2025 in Cancers
Verified
Journal Article
Open access
PDF file
VRValèria Richart
Valèria Richart
MGMeritxell Costa Grau
Meritxell Costa Grau
MMMaría Muní
María Muní
IAIgnacio Asiain
Ignacio Asiain
RSRafael Salvador
Rafael Salvador
CNCarlos Nicolau
Carlos Nicolau
Background/Objectives: Magnetic resonance imaging (MRI) and MRI–ultrasound (US) fusion-targeted biopsy have improved prostate cancer diagnosis, particularly for clinically significant disease. However, the added value of combining systematic biopsy with targeted biopsy remains debated. This study aimed to evaluate the diagnostic accuracy of MRI–US fusion-targeted and systematic transperineal biopsies in detecting prostate cancer and explore the correlation between PI-RADS score and histology. Methods: We retrospectively analyzed 356 patients with 452 MRI-detected lesions who underwent both MRI–US fusion-targeted and transperineal systematic biopsies between 2020 and 2023. Clinically significant prostate cancer (csPCa) was defined as International Society of Urological Pathology (ISUP) grade ≥ 2. Diagnostic performance metrics (sensitivity, specificity, and accuracy) were calculated for each technique using the combined result as a reference. Subgroup analysis was performed for patients under active surveillance. Results: Prostate cancer was diagnosed in 323 of 452 lesions (71%) and csPCa in 223 lesions (49%). Targeted biopsy demonstrated higher sensitivity (93.7%) and accuracy (79.9%) than systematic biopsy (85.7% sensitivity and 77.6% accuracy), although systematic biopsy provided slightly higher specificity. Systematic biopsy alone identified 8.2% of PCa cases missed by targeted biopsy and upgraded 9.9% of lesions to csPCa. csPCa detection increased with PI-RADS score (23% in PI-RADS 3 and 73% in PI-RADS 5). In active surveillance patients, csPCa was found in 65% of lesions. Conclusions: MRI–US fusion-targeted biopsy improves csPCa detection, but systematic biopsy remains valuable, especially for identifying additional or higher-grade disease. The combined approach provides an optimal diagnostic yield, supporting its continued use in both initial and repeat biopsy settings.

9 July 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
VRValèria Richart
Valèria Richart
MGMeritxell Costa Grau
Meritxell Costa Grau
MMMaría Muní
María Muní
IAIgnacio Asiain
Ignacio Asiain
RSRafael Salvador
Rafael Salvador
CNCarlos Nicolau
Carlos Nicolau
Background/Objectives: Magnetic resonance imaging (MRI) and MRI–ultrasound (US) fusion-targeted biopsy have improved prostate cancer diagnosis, particularly for clinically significant disease. However, the added value of combining systematic biopsy with targeted biopsy remains debated. This study aimed to evaluate the diagnostic accuracy of MRI–US fusion-targeted and systematic transperineal biopsies in detecting prostate cancer and to explore the correlation between PI-RADS score and histology. Methods: We retrospectively analyzed 356 patients with 452 MRI-detected lesions who underwent both MRI–US fusion-targeted and transperineal systematic biopsy between 2020 and 2023. Clinically significant prostate cancer (csPCa) was defined as ISUP grade ≥ 2. Diagnostic performance metrics (sensitivity, specificity, and accuracy) were calculated for each technique using the combined result as reference. Subgroup analysis was performed for patients under active surveillance. Results: Prostate cancer was diagnosed in 323 of 452 lesions (71%), and csPCa in 223 lesions (49%). Targeted biopsy demonstrated higher sensitivity (93.7%) and accuracy (79.9%) than systematic biopsy (85.7% sensitivity, 77.6% accuracy), although systematic biopsy provided slightly higher specificity. Systematic biopsy alone identified 8.2% of PCa cases missed by targeted biopsy, and upgraded 9.9% of lesions to csPCa. csPCa detection increased with PI-RADS score (23% in PI-RADS 3, 73% in PI-RADS 5). In active surveillance patients, csPCa was found in 65% of lesions. Conclusions: MRI–US fusion-targeted biopsy improves csPCa detection but systematic biopsy remains valuable, especially for identifying additional or higher-grade disease. The combined approach provides optimal diagnostic yield, supporting its continued use in both initial and repeat biopsy settings.

24 April 2025 in Journal of Medical Case Reports
Verified
Journal Article
Open access
PDF file
VRValèria Richart
Valèria Richart
ACAngel Castillo-Fortuño
Angel Castillo-Fortuño
AGAna Isabel Garcia-Diez
Ana Isabel Garcia-Diez
Perineural spread in rectal cancer is a rare occurrence, particularly when it extensively disseminates along the lumbosacral plexus, as well as the sciatic and pudendal nerves. Its diagnosis is challenging and represents a critical prognostic factor owing to its association with higher recurrence and metastasis rates. A 55-year-old Spanish female with a history of rectal adenocarcinoma underwent standard treatment, including neoadjuvant chemoradiotherapy, ultra-low anterior resection, and adjuvant chemotherapy. Five years later, a fluorine-18 fluorodeoxyglucose positron emission tomography-computed tomography scan detected a hypermetabolic lesion near the right piriformis muscle and internal iliac vessels, leading to surgical excision and radiotherapy, which confirmed metastasis. Three years after that, the patient presented with right-sided sciatica. Magnetic resonance neurography revealed characteristic features of perineural spread, including thickening, hyperintensity, enhancement, and diffusion restriction of the right sciatic and pudendal nerves, as well as the sacral roots (S1–S4). These findings differed from other neuropathic conditions, such as tumoral compression, traumatic neuropathy, and post-radiotherapy changes. Positron emission tomography-computed tomography and biopsy confirmed adenocarcinoma. Despite additional chemotherapy, the disease progressed, resulting in cerebral, lung, and bone metastases. The patient passed away 1 year later. This case highlights the potential role of the magnetic resonance neurography in the accurate diagnosis of perineural spread in rectal cancer, emphasizing the value of functional magnetic resonance neurography sequences in differentiating it from other causes of neuropathic pain. This is essential for clinicians, as perineural spread is associated with a poor prognosis and necessitates appropriate management.

31 August 2024 in Archivos de Bronconeumología
Verified
Journal Article
Closed access
VRValèria Richart
Valèria Richart
AGArantxa Gelabert
Arantxa Gelabert
AZAnder Zugazaga
Ander Zugazaga

8 August 2026 in Neuroradiology
Verified
Journal Article
Open access
PDF file
OPOmar Andres Pantoja-Burbano
Omar Andres Pantoja-Burbano
MTMaría Tugores-Garcías
María Tugores-Garcías
VRValèria Richart
Valèria Richart
AMAndrés Felipe Mejía-León
Andrés Felipe Mejía-León
JMJosé Maidana-Guanes
José Maidana-Guanes
RRRoy Riascos
Roy Riascos
Purpose Pituitary neuroendocrine tumors (PitNETs) are a heterogeneous group of lesions redefined in the 2022 WHO classification, emphasizing their neuroendocrine nature and biological variability. Despite advances in imaging, radiological reporting of PitNETs remains inconsistent and lacks standardized descriptors. This review aims to summarize the main updates of the 2022 WHO classification and to propose a structured MRI-based reporting framework. Methods A comprehensive literature review was conducted focusing on the 2022 WHO classification and radiological features of PitNETs. Imaging parameters were analyzed to identify reproducible descriptors relevant to tumor morphology, internal composition, enhancement characteristics, and invasion patterns. These parameters were organized into a categorical model analogous to the VASARI framework. Results The proposed model includes 19 standardized MRI descriptors designed to capture key imaging features of PitNETs. Each parameter can be scored categorically to promote consistent interpretation, facilitate multicenter data comparison, and support radiologic–pathologic correlation. The system provides a reproducible structure for reporting that integrates seamlessly with the diagnostic and prognostic context of the 2022 WHO classification. Conclusion The proposed standardized reporting framework introduces 19 reproducible MRI descriptors that collectively address tumor localization, internal composition, enhancement characteristics, and invasion patterns. Beyond their descriptive value, each parameter carries potential clinical implications for tumor subtype identification, surgical approach planning, prediction of resectability, and assessment of prognosis. By providing a structured reporting system aligned with the 2022 WHO classification, this framework has the potential to enhance interobserver consistency, strengthen radiologic–pathologic correlation, and ultimately support more informed and individualized treatment decisions in patients with PitNETs. Prospective multicenter validation will be essential to establish its full clinical utility.